<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01146171</url>
  </required_header>
  <id_info>
    <org_study_id>CA196-007</org_study_id>
    <nct_id>NCT01146171</nct_id>
  </id_info>
  <brief_title>Japanese Phase 1 Study of BMS-844203 (CT322)</brief_title>
  <official_title>A Phase I Multiple Ascending Dose Study of BMS-844203 (CT-322) Monotherapy in Japanese Patients With Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this clinical study is to evaluate the safety and tolerability of CT-322
      monotherapy to determine the recommended dose for phase II and subsequent studies
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <start_date>November 2013</start_date>
  <completion_date type="Anticipated">January 2015</completion_date>
  <primary_completion_date type="Anticipated">January 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Determine recommended dose for Phase 2 study of CT-322</measure>
    <time_frame>Within the first 28 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To assess the plasma pharmacokinetics of CT-322. Pharmacokinetics of CT-322 will be derived from plasma concentration versus time data. The pharmacokinetic parameters to be assessed include Cmax, Cmin, Tmax, AUC (INF), AUC (TAU), T-HALF, etc.</measure>
    <time_frame>Cycle 1: Day 1 to 5, 8, 15, 22 to 26 and 29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess the plasma pharmacokinetics of CT-322. Pharmacokinetics of CT-322 will be derived from plasma concentration versus time data. The pharmacokinetic parameters to be assessed include Cmax, Cmin, Tmax, AUC (INF), AUC (TAU), T-HALF, etc.</measure>
    <time_frame>Cycle 2 and beyond (up to 6 cycle): Day 1 at each cycle and then every 3 cycles thereafter</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess anti-tumor activity of CT-322</measure>
    <time_frame>Every 8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess the effects of CT-322 on plasma VEGF levels</measure>
    <time_frame>Cycle 1: Day 1, 3, 8, 15, 22</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess the effects of CT-322 on plasma VEGF levels</measure>
    <time_frame>Cycle 3: Day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess the presence of anti CT-322 antibodies</measure>
    <time_frame>Cycle 1: Day 1, 15, 22 and 29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess the presence of anti CT-322 antibodies</measure>
    <time_frame>Cycle 3 and beyond (up to 6 cycle): Day 1 at each cycle and then every 3 cycles thereafter</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Neoplasms</condition>
  <arm_group>
    <arm_group_label>BMS-844203 (CT-322)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BMS-844203 (CT-322)</intervention_name>
    <description>Injection, IV, 1 and 2 mg/kg, Weekly, Until disease progression or unacceptable toxicity became apparent</description>
    <arm_group_label>BMS-844203 (CT-322)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Advanced or metastatic solid tumors for whom the standard of care is ineffective or
             inappropriate

          -  Life expectancy of at least 3 months

          -  Eastern Cooperative Oncology Group performance 0-1

        Exclusion Criteria:

          -  Subject has uncontrolled diabetes or hypertension

          -  Clinical significant bleeding diathesis or coagulopathy

          -  Thrombotic or embolic cerebrovascular accident
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol-Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Osaka-Sayama-Shi</city>
        <state>Osaka</state>
        <zip>5898511</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <link>
    <url>http://www.bms.com/clinical_trials/Pages/Investigator_Inquiry_form.aspx</url>
    <description>Investigator Inquiry form</description>
  </link>
  <link>
    <url>http://www.fda.gov/MEDWATCH/safety.htm</url>
    <description>For FDA Safety Alerts and Recalls refer to the following link: http://www.fda.gov/MEDWATCH/safety.htm</description>
  </link>
  <verification_date>February 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 10, 2010</study_first_submitted>
  <study_first_submitted_qc>June 16, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 17, 2010</study_first_posted>
  <last_update_submitted>February 6, 2012</last_update_submitted>
  <last_update_submitted_qc>February 6, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 7, 2012</last_update_posted>
  <responsible_party>
    <name_title>Study Director</name_title>
    <organization>Bristol-Myers Squibb</organization>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

